TYRA

Tyra Biosciences Inc

Apr 09 • 04:00PM ET

36.69

-0.44 -1.19 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE TGTX SRRK MREO TIL MCRB ADAP HOOK XFOR PSTX

| Held by: VTI XBI IWM IBB VXF IWN VTWO SCHA IWC VFMO

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	31.51%	Shs Outstand	53.71M	Perf Week	-4.15%
Market Cap	1.98B	Forward P/E	-	EPS next Y	-2.65	Insider Trans	-3.15%	Shs Float	36.78M	Perf Month	5.61%
Enterprise Value	1.73B	PEG	-	EPS next Q	-0.59	Inst Own	79.18%	Short Float	18.63%	Perf Quarter	21.77%
Income	-119.95M	P/S	-	EPS this Y	-18.63%	Inst Trans	1.47%	Short Ratio	6.99	Perf Half Y	174.42%
Sales	0.00M	P/B	7.60	EPS next Y	-11.29%	ROA	-36.96%	Short Interest	6.85M	Perf YTD	39.56%
Book/sh	4.83	P/C	7.72	EPS next 5Y	-11.77%	ROE	-39.83%	52W High	40.65 -9.74%	Perf Year	363.26%
Cash/sh	4.75	P/FCF	-	EPS past 3/5Y	-15.07% -55.76%	ROIC	-45.35%	52W Low	6.42 471.50%	Perf 3Y	135.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.03% 6.45%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-33.44%	Oper. Margin	-	ATR (14)	2.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.67	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.60	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	14.67	EPS Q/Q	-30.60%	SMA20	-1.59%	Beta	0.93	Target Price	50.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	7.44%	Rel Volume	1.03	Prev Close	37.13
Employees	87	LT Debt/Eq	0.02	Earnings	Mar 02 AMC	SMA200	76.56%	Avg Volume	980.70K	Price	36.69
IPO	Sep 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.24% -	Trades		Volume	1,005,783	Change	-1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-06-26	Initiated	Canaccord Genuity	Buy	$50
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight	$59
Sep-03-25	Initiated	Raymond James	Strong Buy	$35
May-21-25	Resumed	Piper Sandler	Overweight	$33
Jan-07-25	Initiated	UBS	Buy	$28
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy	$22 → $31
Aug-15-24	Initiated	Piper Sandler	Overweight	$33
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$25 → $15
Jun-30-23	Initiated	Wedbush	Outperform	$27
Feb-03-23	Initiated	Oppenheimer	Outperform	$17
Jun-23-22	Initiated	H.C. Wainwright	Buy	$12
Mar-08-22	Upgrade	Jefferies	Hold → Buy	$31 → $27
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	Jefferies	Buy	$19
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	BofA Securities	Buy	$22

Show Previous Ratings

Mar-02-26 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights (PR Newswire)
02:11AM	Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data (MarketBeat)
Feb-23-26 05:30PM	Tyra Biosciences Announces Poster Presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium (PR Newswire) +5.45%
Feb-19-26 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +6.56%
Feb-14-26 09:05AM	Tyra Biosciences price target raised to $53 from $37 at Wedbush (TipRanks)
08:00AM	Loading…
Dec-01-25 08:00AM	Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer (PR Newswire) -7.76%
Nov-12-25 04:05PM	Tyra Biosciences Announces Participation at Upcoming Investor Events (PR Newswire)
Nov-05-25 04:05PM	Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights (PR Newswire)
Aug-22-25 05:38AM	Tyra Biosciences initiates paediatric study for achondroplasia treatment (Clinical Trials Arena)
Aug-21-25 08:00AM	Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia (PR Newswire) +14.26%
Aug-20-25 04:05PM	Tyra Biosciences Announces Participation at Upcoming Investor Events (PR Newswire)
Aug-19-25 09:55AM	Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks) -5.64%
Aug-14-25 04:05PM	Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights (PR Newswire)
Jul-21-25 04:05PM	Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series (PR Newswire)
Jul-08-25 04:05PM	Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 (PR Newswire)
08:00AM	Loading…
Jun-30-25 08:00AM	Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) (PR Newswire) +5.16%
May-12-25 04:05PM	Tyra Biosciences to Participate at Upcoming Investor Conferences (PR Newswire)
May-08-25 04:05PM	Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights (PR Newswire) +10.30%
Mar-27-25 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights (PR Newswire) -5.66%
Feb-11-25 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Jan-29-25 04:05PM	Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors (PR Newswire)
Jan-22-25 08:00AM	Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-10-25 08:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) (PR Newswire)
Nov-13-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-07-24 04:05PM	Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights (PR Newswire) -6.06%
Oct-28-24 07:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) (PR Newswire) -9.30%
Oct-24-24 06:05PM	Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) (PR Newswire) -23.35%
Oct-23-24 04:05PM	Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET (PR Newswire)
Oct-22-24 09:07PM	RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc (GuruFocus.com)
Oct-18-24 02:34PM	BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug (Benzinga) +5.20%
01:01AM	Loading…
Oct-16-24 01:01AM	Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc (GuruFocus.com) +5.89%
Oct-11-24 08:00AM	Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) (PR Newswire)
Sep-11-24 04:05PM	Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire) -5.22%
Sep-10-24 04:05PM	Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer (PR Newswire)
Sep-09-24 09:55AM	Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet (Zacks)
Aug-27-24 07:50PM	Tyra Biosciences, Inc. (TYRA): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 11:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights (PR Newswire)
Jul-02-24 04:05PM	Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) (PR Newswire)
Jun-07-24 12:00PM	Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks)
May-23-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
May-09-24 10:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights (PR Newswire)
May-07-24 04:05PM	Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors (PR Newswire)
Mar-19-24 09:53PM	TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023 (InvestorPlace) +7.89%
09:01PM	Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress (GuruFocus.com)
04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights (PR Newswire)
Mar-05-24 11:27PM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares (GuruFocus.com)
Mar-01-24 12:40AM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares (GuruFocus.com)
Feb-27-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Feb-07-24 04:05PM	Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference (PR Newswire)
03:12AM	President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA) (GuruFocus.com)
Feb-02-24 08:00AM	Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing (PR Newswire) +29.29%
Feb-01-24 05:30PM	Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-22-23 09:00AM	Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 (PR Newswire)
Nov-08-23 04:05PM	Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference (PR Newswire)
Nov-07-23 04:05PM	Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights (PR Newswire) -5.00%
Sep-21-23 08:00AM	Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings (PR Newswire)
Sep-12-23 04:05PM	Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-10-23 04:05PM	Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights (PR Newswire)
Aug-01-23 08:00AM	Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Jun-16-23 08:50AM	Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength (Zacks) +6.25%
Jun-07-23 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet (Zacks) -5.63%
May-25-23 08:00AM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
May-23-23 08:50AM	What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing' (Zacks)
May-22-23 09:55AM	Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade (Zacks)
Apr-09-23 09:30AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.)
Mar-29-23 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-27-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA) (Zacks)
Mar-22-23 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights (PR Newswire) -5.01%
Mar-01-23 08:40AM	Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings? (Zacks)
07:00AM	Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia (PR Newswire)
Feb-22-23 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire) -7.99% -9.04%
Nov-29-22 07:00AM	Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 (PR Newswire)
Nov-24-22 09:55AM	How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184% (Zacks)
Nov-10-22 04:20PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet (Zacks)
Nov-03-22 04:05PM	Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights (PR Newswire) -7.00%
Nov-02-22 04:05PM	Tyra Biosciences Announces Planned Chief Financial Officer Transition (PR Newswire)
Oct-31-22 09:22AM	We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth (Simply Wall St.)
Oct-13-22 08:00AM	Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.46%
Sep-08-22 04:05PM	Tyra Biosciences to Participate at September 2022 Investor Conferences (PR Newswire) +8.24%
Sep-05-22 08:15AM	Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress (PR Newswire)
Aug-04-22 04:05PM	Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights (PR Newswire) +14.97%
May-24-22 08:55AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.) -5.68%
May-05-22 04:05PM	Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights (PR Newswire)
Mar-03-22 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights (PR Newswire) -10.21%
Feb-22-22 04:05PM	Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference (PR Newswire)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +14.48%
Dec-15-21 09:29AM	Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-10-21 04:05PM	Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference (PR Newswire)
Nov-03-21 04:05PM	Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights (PR Newswire) +19.92% +8.25%
Sep-22-21 08:22AM	3 Stocks Insiders Are Buying (Benzinga) -7.11%
Sep-20-21 07:52AM	3 Stocks Insiders Are Buying (Benzinga) -6.83%
Sep-17-21 05:28AM	56 Biggest Movers From Yesterday (Benzinga)
Sep-15-21 10:41AM	Tyra Biosciences stock soars more than 60% on public debut (MarketWatch)
Sep-14-21 09:00PM	Tyra Announces Pricing of Upsized Initial Public Offering (PR Newswire)
06:51AM	Tyra Biosciences upsizes IPO to 9 million shares vs. prior 6.7 million for valuation of up to $626 million (MarketWatch)

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KAPLAN GILLA	Director	Mar 25 '26	Option Exercise	2.25	14,295	32,164	42,526	Mar 27 04:44 PM
KAPLAN GILLA	Director	Mar 25 '26	Sale	36.97	14,295	528,506	28,231	Mar 27 04:44 PM
GILLA KAPLAN	Director	Mar 26 '26	Proposed Sale	37.75	53,172	2,007,153		Mar 26 04:04 PM
GILLA KAPLAN	Director	Mar 25 '26	Proposed Sale	36.97	14,295	528,506		Mar 25 05:36 PM
Daniel Bensen	Officer	Mar 12 '26	Proposed Sale	35.38	8,000	283,000		Mar 12 05:42 PM
Bensen Daniel	Chief Discovery Officer	Feb 12 '26	Sale	32.87	8,000	262,965	146,981	Feb 13 04:30 PM
Daniel Bensen	Officer	Feb 12 '26	Proposed Sale	32.75	8,000	262,000		Feb 12 04:52 PM
Bensen Daniel	Chief Discovery Officer	Jan 12 '26	Sale	28.52	8,000	228,186	154,981	Jan 20 04:30 PM
Daniel Bensen	Officer	Jan 12 '26	Proposed Sale	29.00	8,000	232,000		Jan 12 05:38 PM
MORE ROBERT J	Director	Dec 19 '25	Sale	25.00	10,000	250,000	3,823,425	Dec 19 09:00 PM
Bensen Daniel	Chief Discovery Officer	Dec 12 '25	Sale	22.64	8,000	181,159	162,981	Dec 16 04:30 PM
Daniel Bensen	Officer	Dec 12 '25	Proposed Sale	22.50	8,000	180,000		Dec 12 04:21 PM
MORE ROBERT J	Director	Nov 21 '25	Sale	20.25	246,871	5,000,026	3,833,425	Nov 25 05:00 PM
Alta Partners NextGen Fund II,	Affiliate	Nov 21 '25	Proposed Sale	21.00	256,871	5,394,291		Nov 21 04:26 PM
Bensen Daniel	Chief Operating Officer	Nov 18 '25	Sale	16.07	75,633	1,215,627	220,937	Nov 19 07:30 PM
Bensen Daniel	Chief Operating Officer	Nov 19 '25	Sale	16.32	49,956	815,297	170,981	Nov 19 07:30 PM
Daniel Bensen	Officer	Nov 18 '25	Proposed Sale	16.05	124,589	2,000,000		Nov 18 05:04 PM
Bensen Daniel	Chief Operating Officer	Nov 14 '25	Sale	16.02	110,228	1,765,489	316,642	Nov 17 07:03 PM
Bensen Daniel	Chief Operating Officer	Nov 17 '25	Sale	16.18	20,072	324,798	296,570	Nov 17 07:03 PM
Bensen Daniel	Chief Operating Officer	Nov 13 '25	Sale	16.00	1,111	17,780	426,870	Nov 17 07:03 PM
Daniel Bensen	Officer	Nov 17 '25	Proposed Sale	15.94	20,072	320,000		Nov 17 04:28 PM
Daniel Bensen	Officer	Nov 14 '25	Proposed Sale	15.98	86,339	1,380,000		Nov 14 04:29 PM
Daniel Bensen	Officer	Nov 13 '25	Proposed Sale	16.00	25,000	400,000		Nov 13 05:40 PM
KAPLAN GILLA	Director	Jun 18 '25	Sale	9.78	9,568	93,596	28,231	Jun 20 05:42 PM
KAPLAN GILLA	Director	Jun 17 '25	Sale	10.35	10	104	37,799	Jun 20 05:42 PM
GILLA KAPLAN	Director	Jun 18 '25	Proposed Sale	9.78	9,568	93,596		Jun 18 04:03 PM
GILLA KAPLAN	Director	Jun 17 '25	Proposed Sale	10.35	10	104		Jun 17 04:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 13 '25	Buy	10.20	120,167	1,225,703	10,247,478	Jun 16 08:06 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 12 '25	Buy	10.20	31,307	319,331	10,127,311	Jun 16 08:06 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 16 '25	Buy	10.13	11,813	119,666	10,259,291	Jun 16 08:06 PM
KAPLAN GILLA	Director	Jun 12 '25	Sale	10.31	30,000	309,255	59,623	Jun 16 07:05 PM
KAPLAN GILLA	Director	Jun 13 '25	Sale	10.31	15,000	154,582	44,623	Jun 16 07:05 PM
KAPLAN GILLA	Director	Jun 16 '25	Sale	10.38	6,814	70,726	37,809	Jun 16 07:05 PM
GILLA KAPLAN	Director	Jun 16 '25	Proposed Sale	10.38	6,814	70,726		Jun 16 04:14 PM
GILLA KAPLAN	Director	Jun 13 '25	Proposed Sale	10.31	15,000	154,582		Jun 13 04:22 PM
GILLA KAPLAN	Director	Jun 12 '25	Proposed Sale	10.31	30,000	309,255		Jun 12 04:28 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 09 '25	Buy	10.19	186,850	1,904,002	10,096,004	Jun 11 07:44 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 04 '25	Buy	9.63	997,864	9,609,430	9,695,820	Jun 06 04:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 05 '25	Buy	10.04	213,334	2,141,873	9,909,154	Jun 06 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TYRA

Tyra Biosciences Inc

Upgrade your Finviz experience